These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 1780689)
1. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. Catarino M; Conde R Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689 [TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604 [TBL] [Abstract][Full Text] [Related]
3. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies. Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563 [TBL] [Abstract][Full Text] [Related]
4. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596 [TBL] [Abstract][Full Text] [Related]
5. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497 [TBL] [Abstract][Full Text] [Related]
9. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases. Piantino P; Arosaio E Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697 [TBL] [Abstract][Full Text] [Related]
10. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of TATI and other markers in solid tumors. Taccone W; Mazzon W; Belli M Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686 [TBL] [Abstract][Full Text] [Related]
12. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219 [TBL] [Abstract][Full Text] [Related]
13. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer. Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695 [TBL] [Abstract][Full Text] [Related]
14. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer. Pectasides D; Bourazanis J; Economides N; Pozadzidou P; Gogou L; Koutsiouba P; Athanassiou A Int J Biol Markers; 1993; 8(2):81-7. PubMed ID: 8366300 [TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) in pleural effusions. Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690 [TBL] [Abstract][Full Text] [Related]
16. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma. Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688 [TBL] [Abstract][Full Text] [Related]